Key result
Time in the therapeutic range (TTR) is a complex measurement with significant limitations and biases that must be carefully considered when comparing anticoagulation quality across clinical trials.
This review highlights the limitations of using time in therapeutic range (TTR) as the sole metric for warfarin management quality in clinical trials, emphasizing the need to consider specific out-of-range INR values.
In recent clinical trials, the "quality" of warfarin management has been characterized by the time in therapeutic range (TTR) --with the therapeutic range being an INR between 2.0 and 3.0.In many reviews of recent clinical trials, differences in the TTR have been used comparatively to critique and contrast the trials.However, TTR is a more complex measurement than is commonly appreciated, and many factors that underlie the TTR calculation, which can differ from trial to trial, have not been adequately addressed.This manuscript attempts to explain these issues so as to help the reader understand the factors that contribute to TTR and to understand the limitations of TTR so as to better understand anticoagulation trial results.It also addresses the issue of INRs below or above the therapeutic range, that can differ among trials, that are not provided simply by presenting a TTR value, but that can in a substantial way affect the bleeding risk and embolismprevention likelihood of anticoagulation in a trial.www.jafib.com
No takes yet. Share an insight, caveat, or question.
James A. Reiffel (2017) conducted a review in Atrial fibrillation and venous thromboembolism (Warfarin anticoagulation). Warfarin (TTR assessment) was evaluated. Time in the therapeutic range (TTR) is a complex measurement with significant limitations and biases that must be carefully considered when comparing anticoagulation quality across clinical trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: